AusBiotech is inviting expressions of interest from its corporate members for its new virtual pitching series, BiotechPitch. Its new platform will profile Australian companies to investors internationally and will feature expert industry speakers and commentators offering capital insights and market updates.
Overcoming border closures, the series provides access to local and international investors, and will also be available to the broader and interested biotech community.
Each BiotechPitch will highlight innovative companies in an industry sub-sector, such as regenerative medicine (including cell therapies and immunotherapy), digital health, and diagnostics, and will feature up to five investment opportunities.
Expert speakers will share the virtual stage, providing insights on current investment trends, including sourcing capital, preparing for capital raising, understanding the priorities of investors, and the challenges and opportunities in the COVID-19 era.
The series has been developed as a free-of-charge opportunity for AusBiotech’s corporate members and is part of AusBiotech’s broader Investment Programme. AusBiotech helps Australian life science companies connect with international capital markets and empowers them to be competitive on a global scale. The Programme leads companies to global investment hubs; arranges access to opportunities for collaboration and partnerships; and provides investor support and education, both domestically and internationally.
The BiotechPitch series will be scheduled over the coming months, and AusBiotech invites its corporate members to check their eligibility and express their interest now.
Providing further support to the sector, AusBiotech has developed a range of resources for investors and companies that is specific to the life sciences sector, including:
- Guide to Life Science Investing – to overcome investor hesitancy, the Guide aims to build an improved understanding of the unique life sciences sector to increase the quantity and quality of investment in life sciences companies;
- Roadmap to a successful IPO for life sciences companies - the Roadmap aims to provide life sciences companies with independent, non-proprietary information about becoming an ASX–listed company;
- Code of Best Practice for Reporting by Life Science Companies - ASX and AusBiotech strongly encourage companies in the life science sector to adopt best practice in reporting events to investors; and,
- Guide for Life Science Company Directors - to support and enhance the performance of boards of directors leading public and private life science companies.
See AusBiotech’s investment resources here.